Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based Duchenne muscular dystrophy candidate.

Mar 17, 2025 - 19:02
 0
Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst
After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based Duchenne muscular dystrophy candidate.